CupidQ2 FY22

Cupid Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹365.85P/E: 290.2Market Cap: ₹49.2K CrSector: Personal Products

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Cupid Limited aims to double its revenue in the next 2-3 years through development and expansion plans.
  • FY22 revenue target is approximately Rs.150 crores, with a PAT of at least Rs.20 crores.
  • FY23 revenue is expected to range between Rs.170-180 crores, driven partly by diagnostics sales, targeting a minimum 20% PAT margin.
  • Capacity utilization is strong, with 98% for male condoms and 97% for female condoms.
  • The company anticipates commercial production for IVD diagnostics starting Q4 FY22, expanding business verticals.
  • US market entry is expected to generate a minimum $5 million in the first year with 30-40% profit margins; Cupid will be the second player after Veru Pharma.
  • Marketing budget for female condoms in India may double, responding to slow domestic demand but significant growth potential.
  • Tender opportunities in Tanzania, South Africa, and India are expected to add substantial volume.

See what Cupid management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no direct mention of any current or planned fundraising through equity in the transcript.
  • On debt, it is noted that Cupid Limited has short-term borrowings of around Rs. 8 crores, down from Rs. 11-12 crores previously, primarily for working capital.
  • There is no explicit discussion of new debt or equity fundraising plans in the call.
  • The management mentioned being open to exploring excellent opportunities, but no specific fundraising initiatives were indicated.
  • Overall, the transcript does not reveal any current or future fundraising through debt or equity being planned or underway.

See what Cupid management said on order book — free account, 30 seconds.

Capex plans

Yes
- Cupid Limited has recently completed construction of a new diagnostics plant at Nasik. - Commercial production from the Nasik IVD (In Vitro Diagnostics) facility is expected to start from Q4 FY22. - The company is setting up instruments and starting experimental production in December 2021. - There have been delays in the commissioning of this plant due to supply chain and COVID-related labor/material shortages. - Cupid is exploring marketing plans and partnerships to boost the diagnostics vertical and considering use of tele-marketing for female condoms. - No explicit mention of other specific capex or strategic investments in the transcript, but emphasis is on production expansion, doubling revenue in next 2-3 years from existing and new product lines. - The company is increasing marketing budgets for female condoms, expected to be doubled depending on market response. In summary, the main current/future capital investment is in the diagnostics (IVD) plant at Nasik and related expansion activities.

Track Cupid — get its next earnings analysis in your feed

How does Cupid rank vs peers in Personal Products?

Pro feature
ThisCupid
Rev 2Mar 1

How does Cupid rank in Personal Products?

Compare Cupid against every Personal Products company (Q2 FY22) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

Others in Personal Products this season

  • Anondita Medicare (Q2 FY27)

    Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare

  • Gillette India (Q2 FY27)

    Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear

  • Honasa Consumer (Q2 FY27)

    Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…

  • Emami (Q2 FY27)

    Volume growth for domestic business recorded 43% in Q2 and 26% on a like-to-like basis, indicating strong demand. Key concall takeaways from Emami Ltd's Q2…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →